887147-21-9Relevant articles and documents
Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IκB kinase
Kempson, James,Guo, Junqing,Das, Jagabandhu,Moquin, Robert V.,Spergel, Steven H.,Watterson, Scott H.,Langevine, Charles M.,Dyckman, Alaric J.,Pattoli, Mark,Burke, James R.,Yang, XiaoXia,Gillooly, Kathleen M.,McIntyre, Kim W.,Chen, Laishun,Dodd, John H.,McKinnon, Murray,Barrish, Joel C.,Pitts, William J.
scheme or table, p. 2646 - 2649 (2009/12/31)
A new series of tricyclic-based inhibitors of IKK have been derived from an earlier lead compound. The synthesis and structure-activity relationships (SAR) are described. Compound 4k inhibited TNF production in rats stimulated with LPS.
1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY
-
, (2010/11/24)
The present invention provides for tricyclic compounds having the formula (I) wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
8H-IMIDAZO[4,5-D]THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
-
Page/Page column 59-60, (2008/06/13)
The present invention provides for thiazolopyridine-based tricyclic compounds having the formula (I) wherein R1, R2, R5 and R6 are as described herein. The present invention further provides pharmaceutical compo